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ABSTRACT 
With the aim to develop biomaterials for temporary medical devices, a series of novel 
reducible and/or degradable elastomers have been prepared from PLA-b-PEG-b-PLA 
copolymers photo-crosslinked with diallyl sulfide or pentaerythritol tetrakis(3-
mercaptopropionate). Thermal and mechanical properties, including elastic limit and Young 
modulus, were assessed. Degradation was then evaluated under standard hydrolytic 
conditions. Reducibility of a selected elastomer was then illustrated using 2-mercaptoethanol 
or glutathione as reducing agents. The redox-sensitivity of the selected elastomer and the 
possibility to modulate the degradability were shown. Considering drug eluting elastomeric 
devices applications, anti-inflammatory drug ibuprofen loading was illustrated with the two 
simplest elastomer formulations. A rapid or slow linear release was observed as a function of 
the low or high molecular weight of the triblock pre-polymers. Finally, the cytocompatibility 
of the degradable elastomers was assessed with regard to their potential to favor or inhibit 
L929 murine fibroblasts proliferation as a function of the hydrophilicity/hydrophobicity of the 
triblock copolymers.  
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1. INTRODUCTION 
The interest for novel biomaterials that present elastomeric properties faces a rapid growth 
due to the development of medical devices, tissue engineering and/or repair and scaffolding 
techniques. In particular, degradable elastomers represent an attractive class of biomaterials 
for biomedical applications due to the possibility to match their mechanical properties with 
body tissues, while accessing a broad range of degradation rates that can be adjusted directly 
by polymer chain natures, crosslink density and crosslink nature. As a result of the high 
potential of biomedical applications and of the possibility to finely tune their properties, it is 
therefore no surprise that a large diversity of degradable elastomers is proposed as illustrated 
in recent reviews.
[1, 2]
  
Among them, one can distinguish between thermoplastic elastomers, that are physically 
crosslinked, and chemically crosslinked elastomers. Degradable thermoplastic elastomers 
being semi-crystalline, they undergo a heterogeneous degradation and release profiles as well 
as non-linear loss of properties with degradation, which limits their use in tissue engineering 
and controlled drug delivery applications.
[3, 4]
 On the other hand, degradable crosslinked 
elastomers generally degrade by combination of bulk and surface erosion, which assures a 
constant 3D structure throughout the hydrolysis process as well as a linear drug release profile 
than can be of benefit for soft tissue engineering applications.
[5]
 In the recent years, 
crosslinked elastomers have therefore attracted attention for controlled delivery of drugs and 
proteins.
[6-11]
 Besides their structure, ie. thermoplastic vs. crosslinked elastomers, another 
distinction can be done in terms of materials used. Considering the objectives and the existing 
industrial elastomeric materials, most described degradable elastomers are based on polyesters 
or polyurethane backbones, although polycarbonate, mainly poly(1,3-trimethylene 
carbonate),
[12]
 can also be found. Degradable elastomers are therefore generally produced by 
polycondensations/polyadditions (eg. poly(polyol sebacate) and poly(diol citrate), 
diisocyanate and -dihydroxyoligoesters)[13-18] or by thermal-or photo-radical curing of 
double bonds bearing prepolymers (eg. (meth)acrylated or fumarate containing polyesters)
[19-
22]
. In the frame of biomedical applications and drug eluting systems, some parameters should 
however be taken in consideration for the selection of optimal elastomeric materials. A first 
one is the biocompatibility of the materials: for that reason, it is generally recognized that 
isocyanate-based materials should be banned and many researches toward nonisocyanate PU 
are currently undertaken.
[23, 24]
 A second one is the drug friendly character of the production 
process: in this regard harsh synthesis and crosslinking conditions such as high reaction 
temperature, long reaction time, and vacuum that are often needed during the preparation of 
thermo-cured should be avoided. Last but not least, the regulatory aspects for the medical 
applications market, ie. the approval of the proposed elastomers by the regulatory agencies 
(EMA, FDA etc.)  is mandatory. 
This combination of features led us to investigate the possibility to use aliphatic copolyesters 
derivatives as potential elastomeric biomaterials for temporary medical devices. Being 
approved for biomedical applications poly(-caprolactone) (PCL), poly(glycolic acid) (PGA) 
or poly(lactic acid) (PLA) and their block copolymers are indeed the most frequently utilized 
degradable synthetic polymers in this field. We therefore described recently various 
approaches to yield aliphatic polyester elastomers both on the thermoplastic
[25, 26]
 and the 
photo-crosslinked network approaches based on methacrylate
[27]
 and thiol-yne chemistries
[28]
. 
In particular, our aim is to fulfill the gap between existing degradable polymeric networks 
with weak mechanical properties, typically hydrogels and stiffer ones, typically used for bone 
repair.
[29]
 Indeed, soft elastomeric materials with typical Young’s moduli in the range 1 to 500 
MPa pave the way to all soft tissue applications ranging from skin (typically 1MPa) to 
ligament (typically few hundreds of MPa), whereas hydrogels and thermosets are more suited 
for extracellular matrix and bone applications, respectively.
[30]
  In addition, besides 
mechanical properties, the degradation time frame is also important for applications. Aliphatic 
polyesters are known to exhibit various degradation kinetics, that can be easily modulated by 
controlling the macromolecular parameters (crystallinity, hydrophobicity of the ester units, 
molecular weight),
[31]
 or the nature of the crosslinkers,
[27]
 which makes same appropriate 
candidates for elastomeric degradable biomaterials.  
Finally, considering the development of smarter biomaterials, one should also consider 
stimuli-responsiveness in order to control the life-time of the considered materials. In this 
regard, reducible bonds that may be cleaved by biologically relevant reducers, like 
glutathione, have recently attracted attention among polymer chemists. Glutathione (GSH) is 
considered to be the major thiol-disulfide redox buffer of the cell.
[32]
 It plays important roles 
in the maintenance of intracellular redox state and as an antioxidant, cellular protectant and 
regulatory signaling molecule. It has been reported that in the cytosol and nuclei, the 
concentration of GSH reaches 10 mM, while outside the cell the concentration reduces to 
about 2–20 M.[33] In particular, in vivo studies on mice showed that in the tumor tissues at 
least 4-fold higher concentrations of GSH were present, compared to the normal tissue.
[34, 35]
 
As a consequence, GSH-responsive polymers have been mainly developed for drug delivery 
approaches. For example redox-releasing micelles, redox-unveiling nanoparticles and other 
nanoscales assemblies have been described.
[36, 37]
 On the other hand, only few examples of 
reducible elastomers have been reported so far. One can cite polydisulfide networks proposed 
as photo-healable or self-healable materials,
[38, 39]
 or reducible PNIPAAm
[40]
 or PEG 
hydrogels.
[41-43]
 However, to the best of our knowledge, apart from the PCL-SS-PCL network 
reported by our group,
[44]
 none of these structures combine elastomeric properties, 
degradability (even if excretable) and biocompatibility. PCL-SS-PCL network was generated 
under oxidative conditions starting from thiol-functional PCL. Although interesting, one 
limitation with regard to medical device applications is however the rather limited availability 
of the starting material (gram scale). 
In the present work, we aim therefore at combining in degradable elastomers various features 
that would be of advantage for soft tissue-related medical devices. In more details we report 
on elastomers combining i) a large availability of starting materials thanks to the use of 
industrially relevant PLA-PEG copolymers, ii) a mild crosslinking via photochemistry, iii) a 
tunable and/or bimodal degradation thanks to the combination of homogenous hydrolytic 
degradability provided by PLA-PEG copolymers, and of stimuli-responsive degradability 
thanks to reducible disulfide bonds of diallyl sulfide, an agent known for its chemopreventive 
activity against some human cancers,
[45-47]
 and finally iv) drug loading ability with linear drug 
release profile.   
 
2. EXPERIMENTAL SECTION 
2.1. Materials 
Dihydroxy poly(ethylene glycol) (PEG1K Mn = 1000 g/mol; PEG2K Mn = 2000 g/mol), tin(II) 
2-ethylhexanoate (Sn(Oct)2, 95%), triethylamine (99%), diallyl sulfide (AS, 97%), 
pentaerythritol tetrakis(3-mercaptopropionate) (PETMP, > 95%), 1-hydroxycyclohexyl 
benzophenone (Irgacure®184, I184, 99%), 2,2-dimethoxy-2-phenylacetophenone 
(Irgacure®651, I651, 99%), methacryloyl chloride (> 97%), diethyl ether and 
dichloromethane were purchased  from Sigma-Aldrich (St-Quentin Fallavier, France). D,L-
lactide  (D,L-LA) was purchased from Purac (Lyon, France). PrestoBlueTM, modified Eagle's 
medium (MEM), horse serum, penicillin, streptomycin, Glutamax and Dulbecco’s Phosphate 
Buffered Saline (DBPS) were purchased from Invitrogen (Cergy Pontoise, France). Cellstar® 
polystyrene tissue culture plates (TCPS) were purchased from Greiner Bio-One (Courtaboeuf, 
France). All chemicals and solvents were used without purification with exception of 
dichloromethane which was dried over calcium hydride before distillation and use.   
 
2.2. Characterizations 
Molecular weights were determined by Size Exclusion Chromatography (SEC) using a 
Waters equipment fitted with a 60 cm long 5 µm mixed C PLgel column as the stationary 
phase, tetrahydrofuran (THF) at 1 ml/min flow rate as the mobile phase, and a Waters 410 
refractometric detector. Typically, polymer (10 mg) was dissolved in THF (2 ml) and the 
resulting solution was filtered on a 0.45 µm Millipore filter before injection of 20 µL of 
sample solution. Mn and Ð were expressed according to calibration using polystyrene 
standards. 
1
H and 
13
C NMR spectra were recorded at room temperature using an AMX300 
Bruker spectrometer operating at 300 MHz. Deuterated chloroform or deuterated 
dimethylsulfoxide were used as solvents, and chemical shifts were expressed in ppm with 
respect to tetramethylsilane (TMS). Infrared spectra were recorded on a Perkin-Elmer 
Spectrum 100 FT-IR spectrometer. The thermal properties of the polymers were characterized 
by differential scanning calorimetry (DSC). DSC measurements were carried out under 
nitrogen on a Perkin Elmer Instrument DSC 6000 Thermal Analyzer. Samples were submitted 
to a first heating scan to 110 °C (5 °C.min
-1
) followed by a cooling to -65 °C (5 °C.min
-1
) and 
a second heating scan  to 200 °C (5 °C.min
-1
). Glass transition temperature (Tg) was 
measured on the second heating ramp. PrestoBlueTM absorption was quantified with a 
Thermo Scientific Multiscan® FC microplate photometer. 
 
 
2.3. Synthesis of crosslinkable PLA-b-PEG-b-PLA triblock copolymers 
Methacrylated PLA-b-PEG-b-PLA triblock copolymers were prepared according to the 
procedure already reported by our group.
[27]
 In a first step, triblock copolymers with targeted 
molecular weight of 3300 g/mol and 10000 g/mol were prepared by adjusting the ratios of 
D,L-LA with respect to the PEG macroinitiators. PLA-PEG-PLA triblocks were obtained with 
a typical yield of ca. 90%.  
In a second step, PLA-b-PEG-b-PLA triblock copolymers were reacted with methacryloyl 
chloride according to the procedure described in our previous work.
[27]
  Methacrylated PLA-
PEG-PLA triblock copolymers were obtained with a methacrylation yield superior to 70% 
and kept in a dark place.  
1
H NMR (300 MHz; CDCl3): δ (ppm) = 6.2 and 5.6 (s, 2H, 
CH2=C(CH3)) 5.2 (m, 1H, CO-CH(CH3)-O), 4.3 (m, 1H, CO-CH(CH3)-OH and 2H CH2-
CH2-O(CO)), 3.6 (s, 4H, CH2-CH2-O), 1.9 (s, 3H, CH2=C(CH3))  1.5 (m, 3H, CO-
CH(CH3)-O). 
Methacrylation efficiency was calculated according to Equation 1. 
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2.4. Elastomers photo-crosslinking 
Typically, methacrylated PLA-b-PEG-b-PLA triblock copolymers (2.5 g) were dissolved in 
acetone (5 mL) with predetermined amounts of Irgacure®184 and/or Irgacure®651 as 
photoinitiators and diallyl sulfide (A) and/or pentaerythritol tetrakis(3-mercaptopropionate) 
(P) as crosslinkers. Elastomers formulations are listed in Table 1. The obtained viscous 
solutions were poured in silicon vessels and let to dry slowly under a hood for 16 hours in the 
dark. The resulting films were further dried at room temperature under reduced pressure (10
-1
 
bar) for 1 hour. The films obtained were cross-linked for 10 minutes (5 minutes for each side) 
under UV light using DYMAX Light Curing System Model 2000 Flood.  
Sol-gel analysis was conducted by swelling the films in CH2Cl2 at room temperature. Initial 
CH2Cl2 was replaced few times by fresh solvent over a 24h period to allow full extraction of 
unreacted prepolymers and crosslinkers.  The solvent was removed, the films were dried, and 
the gel content (Gc) was estimated by calculating the ratio between the films weights before 
and after extraction.   
 
2.5. Mechanical analyses of elastomers 
Elastomer samples (typically 12×2×0.6 mm) were prepared for tensile tests. Analyses were 
conducted at 37°C on an Instron 4444 tensile machine with a crosshead speed of 5 mm/min . 
Each sample was analysed in its dry (D) and hydrated (H) state. Hydration was obtained by 
soaking samples in a phosphate buffer solution (PBS, pH 7,4) at room temperature for 1h. 
Each sample was then analysed in triplicate and Young’s modulus (E, MPa), ultimate stress 
(break, MPa), ultimate strain (break, %) and elastic limit (yield, %) were expressed as the mean 
value of the three measurements. E was calculated using the initial linear portion of the 
stress/strain curve.  
 
2.6. Elastomers swelling and degradation 
Samples of elastomer films were weighed and placed in phosphate buffer solution (PBS, pH 
7.4) at 37°C. The swelling percentage was calculated based on the initial dry samples weights 
according to the following equation. 
   
       
  
       Equation 2 
where Wh is the weight of the hydrated sample after t hours in PBS and W0 the initial dry 
weight of the sample. Each result was expressed as the mean value of three measurements. 
Degradation was carried out in PBS at 37°C under stirring for various periods of time. After 
incubation the sample was gently dried on absorbent paper, weighed and further dried under 
reduced pressure at 40°C. The degradation was assessed using water uptake and weight loss. 
The water uptake was calculated based on the dry samples weights after degradation using the 
following equation 
    
       
  
     Equation 3 
where Wh is the hydrated weight and Wd the dry weight of the sample after a defined period 
of time in PBS. The weight loss was calculated using the following equation 
     
       
  
     Equation 4 
where Wd is the dry weight of the sample after a defined period of time in PBS and W0 the 
initial dry weight of the sample before degradation. Each result was expressed as the mean 
value of three measurements. 
To evaluate the reducibility of disulfide bonds present in the samples crosslinked with AS, 
degradation experiments were run under the same conditions by adding 2-mercaptoethanol 
(10 mM) or glutathione (GSH, 10 mM) in PBS.  
 
 
 
2.7. Drug loading and drug release  
Ibuprofen was chosen as an anti-inflammatory model drug to evaluate the loading and release 
capacities of the elastomers. In a typical experiment, a 300 mg sample of elastomer was 
soaked in 10 mL of a 4 wt% solution of ibuprofen in acetone under mild shaking. After 24 
hours, the sample was withdrawn from the solution and dried under reduce pressure until 
constant mass was obtained. The loaded sample was weighed (WLS). This procedure was done 
with n = 6 for each elastomer.  
For release study, ibuprofene-loaded elastomers were immersed in glass vials containing 10 
mL PBS (pH 7.4). The samples were incubated at 37˚C under mild shaking. Each release 
experiment was done in triplicate. At predetermined time intervals, the PBS with released 
ibuprofene was replaced by fresh PBS. The amount of released ibuprofene in PBS was 
evaluated by HPLC (WatersTM 717 plus Autosampler) using a 50:50 mixture of water:TFA 
(1000:1) and acetonitrile:TFA (1000:1) at 1 mL/min flow rate and a photodiode array detector 
(λmax=264nm). Before analysing by HPLC, solutions were filtered and 2ml of EtOH was 
added. 
For determination of the drug loading, samples (n = 3 for each elastomer) were soaked in 10 
ml of acetone and let to swell for 48 h under gentle stirring. Release medium containing 
ibuprofen was collected and replaced with fresh acetone. The same procedure was repeated 3 
times. Collected solutions were gathered before evaporation of solvent under reduced pressure 
to dryness. Released ibuprofen was then dissolved in 10 ml of PBS/EtOH (50:50) solution for 
HPLC quantification. 
 
 
2.8. Elastomers cytocompatibility 
Mouse L929 fibroblasts (L929) were cultured in modified Eagle's medium (MEM) containing 
10% horse serum, penicillin (100 µg/mL), streptomycin (100 µg/mL), and Glutamax (1%). 
Elastomer films were disinfected in ethanol (95%) for 30 minutes before immersion in a 
solution of sterile PBS containing penicillin and streptomycin (1 mg/mL) and incubation for 
48 hours at 37°C. Films were then rinsed 3 times with sterile PBS before soaking for 12 hours 
in sterile PBS. Before drying, swelled sterile elastomers films were stamped to fit the size of 
the wells of 24-well cell culture plates. The in vitro cytocompatibility of the elastomers was 
assessed by following the proliferation of L929 on the surface of elastomer films. Films were 
placed in polystyrene 24-well tissue culture plates (TCPS) and seeded with 50 000 cells. Cells 
proliferation after 1, 2, 3 and 7 days was evaluated using the PrestoBlue
TM 
assay that reflects 
the number of living cells present on a surface at a given time point. At scheduled time points, 
culture medium was removed and replaced by 1 mL of fresh medium containing 10% of 
PrestoBlue
TM
. After 2 hours of incubation at 37°C, aliquots of 100 µL were taken and 
analysed for UV absorbance at 570 nm and 595 nm. All data points and standard deviations 
correspond to measurements in triplicate. 
3. RESULTS AND DISCUSSION 
3.1. Elastomers synthesis and characterizations 
Few years ago, our group reported on PLA50-b-PEG-b-PLA50 based networks exhibiting 
tunable elastomeric properties and degradability that were controlled by the nature of the 
crosslinkers.
[27]
 In particular, mechanical properties were close to the ones of soft cartilage or 
vascular vessels (E ≈ 2-5 MPa, break up to 90%, yield up to 30%), whereas a linear 
degradation was observed over 6 months. In the present work, we aim at combining the 
hydrolytic degradability of this class of elastomers with, on the one hand the highly desired 
stimuli-responsive crosslinks to gain increased control over the mechanical and degradation 
behavior of the elastomers,  and on the other hand, the facile photoradical thiol-ene addition. 
 
For that purpose, two PLA-b-PEG-b-PLA triblock copolymers with amorphous PD,L-LA 
blocks were first synthesized: a low molecular weight triblock (PLA9-PEG2k-PLA9, MnNMR = 
3300 g/mol) with higher hydrophilicity (EG/LA = 2.5) and a medium molecular weight 
triblock (PLA62-PEG1k-PLA62, MnNMR = 12300 g/mol) with higher hydrophobicity (EG/LA = 
0.2). Classical ring opening polymerization of D,L-lactide using PEG1K or PEG2K as a 
macroinitiator was used. Good control over the polymerization was obtained as shown by the 
comparison of targeted and experimental molecular weights determined by NMR analyses 
and by the limited dispersities determined by SEC analyses (Table S1). Chromatograms 
resulting from SEC analysis were monomodal and used to confirm the absence of PLA 
homopolymer. The apparent discrepancy between MnNMR and MnSEC is attributed to the 
amphiphilic character of the block copolymer with higher difference observed with increasing 
hydrophilicity.
[48]
 
 
In a second step photo-crosslinkable triblock copolymers were prepared by reaction between 
the PLA-b-PEG-b-PLA triblock copolymers and methacryloyl chloride. Using Equation 1, 
methacrylation efficiencies were calculated from the integrations of NMR resonance peaks at 
6.1 and 5.7 ppm belonging to the alkenyl protons, and at 4.3 ppm belonging to the PEG and 
non methacrylated PLA chain ends. Methacrylation efficiencies were 70% and 100% for 
PLA62-PEG1k-PLA62 and PLA9-PEG2k-PLA9, respectively. A typical NMR spectrum is 
provided as Supplementary Information (Figure S1). No significant change in molecular 
weight distribution was found by SEC analyses confirming that triblock copolymers were not 
degraded under these conditions (Table S1). The lower methacrylation yield for PLA62-
PEG1k-PLA62 is assumed to be due to the higher molecular weight making the hydroxyl end 
groups less accessible for reaction in the copolymer large random coil compared to PLA9-
PEG2k-PLA9. 
 
Table 1. Elastomers formulations 
 
Sample name Irgacure®184 
(mol % / alkene) 
Irgacure®651 
(mol % / alkene) 
PETMP 
(mol % / 
alkene) 
AD 
(mol % / alkene) 
E12-Ø 10 0 0 0 
E12-P 0 10 25 0 
E12-A 10 0 0 25 
E12-P-A 5 5 12.5 12.5 
E3.5- Ø 10 0 0 0 
E3.5- P 0 10 25 0 
E3.5- A 10 0 0 25 
E3.5- P-A 5 5 12.5 12.5 
 
Elastomeric biomaterials were then prepared with various formulations including the two 
chosen crosslinkers, namely diallyl sulfide (A) and pentaerythritol tetrakis(3-
mercaptopropionate) (P) (Scheme 1). In particular, diallyl sulfide was chosen as it is a non 
toxic garlic-derivative that presents in its free form various benefits for human health 
including a reported chemopreventive activity against some human cancers such as colon, 
lung and skin cancers.
[45-47]
 Samples were named according to the following system: E was 
used for elastomer, 12 or 3.5 were used to indicate the molecular weight of the methacrylated 
triblock copolymer (12000 g/mol or 3500 g/mol), Ø, A and P were used for no crosslinker, 
diallyl sulfide and pentaerythritol tetrakis(3-mercaptopropionate), respectively. 
 
 
Scheme 1. Formulation of elastomers (X= 3.5 or 12 depending on the molecular weight of the 
initial triblock copolymer). 
 
Elastomers formulations are listed in Table 1. When present, crosslinkers molar 
concentrations were fixed to 25% with respect to the alkene groups. Photo-initiators were 
selected depending on the nature of the crosslinker: Irgacure® 184 was used in combination 
with diallyl sulfide (acrylic crosslinking), Irgacure® 651 was used in combination with 
pentaerythritol tetrakis(3-mercaptopropionate) (thiol-ene crosslinking). As little to no 
influence of photoinitiator was found in our previous work, a low concentration of 10% of 
photoinitiator with respect to the alkene groups was chosen. Low concentration should 
guaranty a higher biocompatibility of the final elastomers although the chosen photoinitiators 
have long track records in the field of biomaterials. All elastomers were photo-crosslinked 
under UV (5 min/side) with 75 mW/cm² intensity.  
 
Table 2. Elastomers gel content and thermal properties. 
 
Sample name Gc (%) Tg (°C) Tm(°C) ΔHm (J/g) 
E12-Ø 97 19 / / 
E12-P 97 18 / / 
E12-A 96 15 / / 
E12-P-A 96 21 / / 
E3.5- Ø 96 -12 26 11 
E3.5- P 95 nd* 22 4 
E3.5- A 93 nd 21 10 
E3.5- P-A 92 nd / / 
*not determined: of too low intensity to be detected under the analyses conditions 
 
The extent of crosslinking was assessed by determination of the gel contents (Gc). In all 
samples Gc was superior to 92% and no significant differences between the formulations was 
found (Table 2). It is to note that despite a lower methacrylation for PLA62-PEG1k-PLA62, 
crosslinking was highly efficient.  
For E12 elastomers, a limited increase of Tg (15°C to 21°C) was observed with crosslinking 
compared to the initial Tg value of 15°C for methacrylated PLA62-PEG1k-PLA62 (Table 2 and 
Table S2). Such a limited increase corresponds to a limited restriction of chains mobility, 
which is in agreement with the looser network expected for longer pre-polymer chains (12000 
g/mol). The highest Tg value (21°C) was obtained when both crosslinkers were used. In 
addition, although the pre-polymer showed a melting temperature of PEG block around 30°C, 
no melting temperature was found for E12 elastomers in agreement with the amorphous nature 
of the PLA blocks and the hindered crystallization of PEG blocks due to the crosslinking.  
In opposition, for E3.5 elastomers a strong impact of crosslinking was observed on Tg. Starting 
from -37°C for the pre-polymer, Tg values reached -12°C for E3.5- Ø. This is in agreement with 
our previous study and with the shorter (3500 g/mol) pre-polymer chains.
[27]
 For the three 
other E3.5 elastomers, Tg could not be determined. It is our belief that Tg was either hidden or 
disturbed by the melting peak around 20°C, or was of too weak intensity to be observed. The 
melting temperature of ca. 20°C was due to the crystallization of PEG and was ca. 15°C lower 
than the one found for the pre-polymer in agreement with a crystallization made more 
difficult by the network structure, and with the lower melting enthalpy values compared to the 
pre-polymer. 
 
3.2. Elastomers mechanical properties 
Tensile tests were performed to evaluate the mechanical properties of the elastomers with 
respect to their formulations. Taking into account that the elastomers should be implanted 
they were studied in both the dry and hydrated state at 37°C. Results are listed in Table 3. 
 
A clear influence of the molecular weight and composition of the pre-polymer is found. In 
more details, Young’s modulus is inferior to 0.9 MPa for all E12 elastomers and superior to 
1.4 MPa for all E3.5 elastomers with a maximal value of 2.2 MPa. These values are in the low 
range for soft tissues (vascular vessel, soft cartilage). The invert is found for all other 
parameters with higher values of ultimate stress (break), ultimate strain (break) and elastic 
limit (yield) for E12 elastomers compared to E3.5 elastomers. In more details, for E3.5 
elastomers break is below 0.9 MPa, break is below 45% and yield is inferior to 25%. These 
values tend to show that E3.5 elastomers are indeed quite weak materials with low elasticity. 
Due to the high EG/LA ratio (2.5) E3.5 elastomers behaviour could be compared to some 
extent to hydrogels. In opposition, E12 elastomers present properties close to the ones of 
mentioned soft tissues, with break in the range 1.1-2.9 MPa, break in the range 180-340% and 
yield in the range 70-154%. Of particular interest is the uniaxial elastic limit which is above 
100% for most E12 samples making them more appropriate for high deformation applications. 
They fit the definition of elastomers according to ASTM or ISO norms where some 
characterizations are done at 100% strain.
[49]
  
 
Table 3. Elastomers mechanical properties in the dry (D) and hydrated state (H) at 37°C 
(Young’s modulus (E), ultimate stress (break), ultimate strain (break) and elastic limit (yield)) 
 
Sample name E (MPa) break (MPa) break (%) yield (%) 
E12-Ø D 0.66 ± 0.09 1.98 ± 0.56 200 ± 49 144 ± 3 
E12-P D 0.53 ± 0.08 1.83 ± 0.56 314 ± 25 96 ± 10  
E12-A D 0.51 ± 0.14 1.12 ± 0.17 192 ± 1 124 ± 4 
E12-P-A D 0.67 ± 0.27 1.95 ± 0.03 242 ± 9 154 ± 36 
E3.5- Ø D 2.20 ± 0.28 0.72 ± 0.05 25 ± 2 20 ± 3 
E3.5- P D 1.58 ± 0.05 0.87 ± 0.04 45 ± 1 25 ± 4 
E3.5- A D 2.07 ± 0.14 0.72± 0.28 15 ± 5 19 ± 4 
E3.5- P-A D 1.63 ± 0.07 0.56 ± 0.07 29 ± 3 21 ± 3 
E12-Ø H 0.87 ± 0.14 2.88 ± 0.22 292 ± 36 139 ± 43 
E12-P H 0.67 ± 0.12 2.07 ± 0.48 341 ± 42 72 ± 3 
E12-A H 0.61 ± 0.14 1.46 ± 0.44 181 ± 13 74 ± 7 
E12-P-A H 0.44 ± 0.03 2.59 ± 0.80 301 ± 34 133 ± 18 
E3.5- Ø H 1.53 ± 0.17 0.27 ± 0.01 21 ± 18 9 ± 1 
E3.5- P H 1.32 ± 0.41 0.44 ± 0.01 21 ± 6 13 ± 3 
E3.5- A H 1.88 ± 0.56 0.51 ± 0.08 15 ± 10 7 ± 2 
E3.5- P-A H 1.37 ± 0.18 0.25 ± 0.05 11 ± 4 9 ± 3 
 
Hydration had  no impact or little impact on the mechanical properties of E12 elastomers with 
exception of break that was slightly increased, in particular for E12-Ø (48% increase). In 
opposition, for the more hydrophilic E3.5 elastomers hydration led to a limited decrease of 
break and a strong decrease of yield of ca. 55%. This result tends to prove that water uptake 
(see next paragraph) leads to a marked plasticization of the E3.5 elastomers.  
Coming to the influence of the crosslinkers, each parameter is influenced differently with 
respect to the nature of the crosslinker. For the Young’s moduli, the elastic limits and ultimate 
stresses, no significant influence was found, with exception for AS crosslinker that lowered 
break values of E12 of about 40-45%. The most significant effect was observed for ultimate 
strains, with break of both E12 and E3.5 being higher with PETMP compared to AS or no 
crosslinker. This is due to the flexible nature of the ether and thioether bonds with PETMP.  
To summarize it is interesting to note that by considering all properties and both the hydrated 
and dry state, the best suited crosslinker depends on the prepolymer used. For E12 (higher 
molecular weight, more hydrophobic), the combination of PETMP and AS provides best 
compromise in terms of elastomeric mechanical properties as shown by sample E12-P-A, 
whereas for E3.5 (lower molecular weight, more hydrophilic) it is PETMP that provides best 
compromise in terms of elastomeric mechanical properties as shown by sample E3.5-P. 
 
3.3. Elastomers degradation and reduction 
In the frame of the degradation study, water uptake was first evaluated. As expected, water 
uptake was slow for the higher molecular weight and more hydrophobic E12 elastomers 
compared to E3.5 elastomers (Figure 1). Evaluation of water uptake was therefore carried out 
over 6 months for E12 but due to their degradation and loss of physical integrity E3.5 samples 
were only analyzed for one month. As can be seen in Figure 1 all samples presented a quasi 
linear water uptake up to one month for E3.5 samples and up to 3 months for E12 samples. 
Above this time point a strong increase of water uptake was observed for E12-Ø and E12-P. 
Water uptakes were important for E3.5 samples with ca. 150% after only one week, in 
agreement with the values previously reported for similar elastomers.
[27]
 In comparison, very 
limited water uptakes were measured for E12 samples with values around 5% after one week, 
and only 40 to 70% after three months. No clear influence of the crosslinkers was observed. 
 
Figure 1. Water uptake of elastomers in PBS at 37°C. For elastomers names, please refer to 
Table 1 (data are expressed as means ± SD and correspond to measurements in triplicate). 
 
Degradation in PBS was in agreement with the water uptake results. As shown in Figure 2, 
elastomers E12 (full lines), due to their low water uptake, presented an induction period 
superior to one month where no evolution of weight loss was detected. Following this initial 
step, weight loss was fast with values in the range 75-80% after three months, and 89-98% 
after six months. In opposition, a rapid weight loss was observed right from the beginning for 
E3.5 (dashed lines), with already between 14% and 21% of loss after one month and almost 
complete degradation at three months (95-100%). No real difference was found between the 
crosslinkers. With exception of E3.5-P-A that presents higher deviation for the two first points at 
one and two weeks, it can be concluded that E3.5 elastomers present a linear degradation over 
a three-month period, whereas E12 elastomers present a typical sigmoidal degradation over a 
six-month period. 
 
Figure 2. Weight loss vs. degradation time for elastomers in PBS at 37°C (data are expressed 
as means ± SD and correspond to measurements in triplicate) 
 
Following these results, we were interested in evaluating the degradability of some elastomers 
prepared with diallyl sulfide that present reducible crosslinks in the form of disulfide bonds. It 
is to note that redox responsive materials have to date mainly been developed for responsive 
drug delivery systems that hold great promise as a tool for improving the pharmacokinetic 
properties of drug compounds. However, although redox responsive drug delivery approaches 
are mainly based on nanoobjects (nanogels, micelles, nanospheres…),[37] drug eluting bulk 
biomaterials may also be key materials in the frame of tissue engineering and medical 
devices. In fact such bulk redox-sensitive materials, especially elastomers, would allow the 
modulation or even the control of the degradation and drug release kinetics of drug loaded 
scaffolds.  
Glutathione is considered to be the major thiol-disulfide redox buffer of the cell with 
physiological average GSH concentrations in the range 1–11 mM.[32, 33] To evaluate the 
bioreducibility of the elastomers, low molecular weight allyl sulfide-containing elastomers 
(E3.5-A) were degraded in presence of GSH (10 mM) using conditions of the literature.
[50]
 
Weight loss as a function of the presence of GSH was followed over 1 month, with fresh 
degradation medium being used at each time point (Figure 3). Under these conditions, the 
degradation of E3.5-A was not significantly impacted by the presence of 10 mM GSH in the 
degradation medium. This result could appear as unexpected considering the reported GSH 
redox-sensitive nanoscales assemblies or hydrogels using similar conditions.
[37, 40-43]
 One 
should however note that in the present study, the bulky nature of the elastomers and their 
hydrolytic degradation ability may explain this result. In more details, for the reported redox-
sensitive hydrogels of PNiPAMM or PEG, there is no increase in acidity due to degradation 
of the material. On the other hand, for the nanosized redox-sensitive micelles and 
nanoparticles where a rapid reduction is aimed, the reducible groups are located at the surface 
and are highly accessible to the GSH. We therefore hypothesize that in our case, the absence 
of significant effect of GSH is due to a combination of factors: i) the limited stability and 
activity of GSH at 37°C under aerobic and acidic conditions,
[51-53]
 ii) the bulkiness of the 
elastomers that decreases the accessibility to the reducible disulfide and may yield a slightly 
more acidic microenvironment as a result of the hydrolytic degradation of the PLA segments.    
 
These points should be further elucidated in future dedicated studies, however to further 
evaluate the redox responsiveness of our reducing elastomer, 2-mercaptoethanol was selected 
as an alternative reducing agent. The use of reducers others than GSH, including dithiothreitol 
or 2-mercaptoethanol, is classically reported in the literature to evaluate redox responsiveness 
of biomaterials.
[40, 54, 55]
For the later, it has been proposed as a GSH model due to its standard 
redox potential (E0 = -0.26 V ) comparable to the standard redox potential of  GSH (E0 = -
0.24 V).
[56-58]
 Like for GSH experiment, low molecular weight allyl disulfide containing 
elastomers (E3.5-A) were degraded in presence of 10 mM 2-mercaptoethanol (Figure 3). After 
1 month, a 62% weight loss was obtained in the presence of 2-mercaptoethanol, against 14% 
in PBS. This result confirms the potential of these redox sensitive elastomers to modulate the 
polyester-based elastomers degradation and eventually drug release profiles. Future studies 
focusing on anaerobic conditions applied to the all range of reducible elastomers should 
follow. 
 
Figure 3. Compared weight losses of reducible E3.5-A elastomer in PBS, PBS/GSH (10 mM) or 
PBS/2-mercaptoethanol (10 mM) (data are expressed as means ± SD and correspond to measurements 
in triplicate). 
 
3.4. Drug loaded elastomers: properties and drug release 
The potential of degradable elastomers as drug eluting biomaterials was finally evaluated with 
the simplest formulations, ie. E12-Ø and E3.5-Ø. Ibuprofen was chosen as an anti-inflammatory 
model drug compound and was loaded in the elastomers by soaking them in a 4 wt% 
ibuprofen solution. Ibuprofen loadings were evaluated by extraction of the drug in acetone 
followed by HPLC quantification. Drug loadings of 3.6±0.6 wt% and 3.1±0.6 wt% were 
calculated for E3.5-Ø and E12-Ø, respectively.  
 
Figure 4. Ibuprofen release profiles from E3.5-Ø and E12-Ø elastomers (data are expressed as 
means ± SD and correspond to measurements with n = 6). 
 
Release studies were performed in PBS (Figure 4). For the E12-Ø elastomer, a 16 % burst 
release is observed during the first hours, which may represent drug that was not distributed 
homogeneously throughout the elastomer and that was located near the surface of the 
samples. The burst release is followed by a slow and nearly constant release rate until day 28. 
Figures 2 and 4 show that the ibuprofen release occurs at a much faster rate than the 
degradation rate, indicating that the release is most likely diffusion controlled from the E12-Ø 
elastomer, similar to previous observations on the release of biologically active agents from 
PLA-based elastomers.
[7]
 
Compared to the E12-Ø elastomer, the ibuprofen release from the E3.5-Ø elastomer is 
significantly faster. A 70 % burst release of is observed, followed by a constant release rate 
until day 2, after which the rate levels off until the release is complete on day 5.  The fast 
release may be due to the high water uptake of the hydrophilic E3.5-Ø elastomer after 
immersion in PBS (Figure 1) and the accompanying rapid weight loss (Figure 2). The loss of 
material after degradation and the high degree of swelling most likely result in a higher 
diffusion coefficient for ibuprofen in the E3.5-Ø elastomer in comparison with the E12-Ø 
elastomer. 
 
3.5. Elastomers cytocompatibility 
An evaluation of cells proliferation was performed on elastomers to assess their 
cytocompatibility and evaluate their suitability for cell culture and cell-contacting biomedical 
applications. Tests were conducted on the L929 fibroblast cell line, as recommended by 
standard ISO 10993-5:2009.
[59]
 Figure 5 shows the proliferation of L929 murine ﬁbroblasts 
over a week on the elastomeric films and TCPS positive control.  
A clear dependence over the hydrophilic/hydrophobic balance of the prepolymers is 
demonstrated. It is clearly visible that L929 fibroblasts adhered and proliferated on the more 
hydrophobic elastomers, ie. the E12 series, whereas proliferation of cells was very limited on 
the more hydrophilic elastomers of the E3.5 series. Such dependence is in accordance with 
previous studies of Garric et al. on PLA-b-PEG-b-PLA skin substitutes.
[60]
 Figure 5 also 
shows two distinct periods for L929 proliferation. From day 1 to day 3 proliferation on the E12 
series is comparable or superior to the one obtained on TCPS control (see close up in Figure 
S2). However at day 7 a stronger proliferation is observed on the TCPS positive control 
compared to E12 elastomers where proliferation is about twice lower than on TCPS. Coming 
to a more detailed analysis of results, the combination of both crosslinkers turns to be 
beneficial with higher proliferation observed on E12-P-A and E3.5-P-A samples compared to the 
other elastomers of the same series (Figure S2). It is even remarkable that at all time points, 
from day 1 to day 3, E12-P-A shows ca. 20% higher proliferation than TCPS control. This 
tendency is more pronounced at early stages and is totally inverted at day 7. These results 
confirm that the proposed elastomers, depending on their hydrophilic/hydrophobic balance are 
either suitable for the growth of ﬁbroblasts (E12 hydrophobic series), or behave more like 
antiadhesion/antiproliferation materials (E3.5 hydrophilic series). Depending on the target 
application, this family of elastomers offers therefore opportunities for the design and the 
development of medical devices. 
 
Figure 5. L929 fibroblasts proliferation on elastomers compared to TCPS control at 1, 2, 3 and 7 
days (data are expressed as means ± SD and correspond to measurements in triplicate). 
 
 
 
4. CONCLUSION 
PLA/PEG-based elastomers have been efficiently prepared using thiol-ene or methacrylate 
photo-curing of PLA-b-PEG-b-PLA triblock copolymers. Depending on the network 
characteristics, in particular the macromolecular parameters of the copolymers used, it was 
possible to modulate the elastomers mechanical properties with elastic limits in the range 10 
to 150% and Young’s moduli in the range 0.5 to 2.2 MPa. Complete and quasi-linear 
degradation was obtained after 3 months in the case of low molecular weight pre-polymers 
and after 6 months, including a 1 month induction period, in the case of higher molecular 
weight pre-polymers. In the frame of stimuli-responsive materials, it was also demonstrated 
with the E3.5-A that disulfide-containing elastomers may be used as redox-sensitive degradable 
systems to modulate/trigger degradation with a 400% increase of weight loss in the presence 
of 2-mercaptoethanol compared to pure PBS. GSH responsiveness was not observed in the 
present work, probably because of the known lower stability of GSH in acidic medium or 
aerobic conditions. Further studies on this particular point should therefore follow. 
Considering the use of such degradable elastomeric biomaterials for the development of 
temporary and drug eluting medical devices, the simplest formulations E3.5-Ø and E12-Ø were 
selected for a proof of concept study. Their loading ability (~3-3.5 wt%) with the anti-
inflammatory ibuprofen and complete drug release over 5 or 30 days as a function of the pre-
polymer used were shown. It was finally shown that depending on the formulation of the 
elastomers and especially the hydrophilicity, opposite behaviours could be reached in terms of 
cells proliferation, that is pro-proliferative or anti-proliferative materials. It is our belief that 
this combination of features may allow one to select the more appropriate elastomer with 
respect to the final application and that they offer opportunities for the design and the 
development of innovative medical devices or tissue engineering scaffolds. 
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Degradable elastomers for soft tissue-related medical devices are proposed. These PLA-PEG 
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ability, as well as a tunable cell compatibility that makes them anti- or pro-proliferative 
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 Figure S1. 1H NMR (300 MHz; CDCl3) of methacrylated PLA9-PEG2k-PLA9 copolymer. 
Crosses correspond to residual solvents and triethylammonium salt.  
Procedure: Ibuprofen standard curve 
Ibuprofen solutions with concentrations in the range 2 µg/mL to 1000 µg/mL were prepared 
in PBS/EtOH (50:50). The analyses were carried out by HPLC (WatersTM 717 plus 
Autosampler) using a 50:50 mixture of water: TFA (1:1000) and acetonitrile: TFA (1:1000) at 
flow rate 1 mL/min and a photodiode array detector (λmax=264nm).  
Concentration (µg/ml) Area 
(µV*sec) 
Ret. Time 
(min) 
Height 
(µV) 
1000 8634198 2,721 1462565 
500 4397773 2,733 851809 
250 2202354 2,736 461141 
100 849546 2,757 185847 
50 83483 2,762 19216 
10 51293 2,759 11626 
2 17861 2,766 4246 
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 Figure S2. L929 fibroblasts proliferation on elastomers compared to TCPS control at 1, 2 and 
3 days (data are expressed as means ± SD and correspond to measurements in triplicate).
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Table S1. Characterizations of copolymers 1 
Sample 
name 
Chain ends Targeted 
EG/LA 
Targeted 
Mn 
(g/mol) 
MnNMR 
(g/mol) 
MnSEC
* 
(g/mol) 
Ð Methacrylation 
(%) 
PLA9-
PEG2k-
PLA9  
hydroxyl 2.5 3296  3300 4700 1.1 - 
PLA9-
PEG2k-
PLA9   
methacrylate 2.5 3296  3580 5700 1.1 100% 
PLA62-
PEG1k-
PLA62 
hydroxyl 0.2 10000 12300 9030 1.5 - 
PLA62-
PEG1k-
PLA62  
methacrylate 0.2 10000 12300 11800 1.4 70% 
*SEC analyses were carried out in THF 2 
 3 
Table S2. Thermal properties of methacrylated pre-polymers and PEG 4 
Polymer Tg 
(˚C) 
Tm 
(˚C) 
ΔH (J/g) 
PEG 2000 -60< 56 235 
PLA9-PEG2k-PLA9  -37 40 50 
PLA62-PEG1k-PLA62 15 29 62 
 5 
 6 
